Product Description
AK101 clinically treats autoimmune diseases by blocking the biological activities of cytokines IL-12 and IL-23.
Mechanisms of Action: IL12 Inhibitor, IL23 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Akeso Pharm
Company Location: Asia Pacific
Company Founding Year: 2012
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Psoriasis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20171655 |
CTR20171655 | P1 |
Active, not recruiting |
Psoriasis |
None |
2025-04-29 |
Patient Enrollment|Treatments |